

MATERIALS LICENSE


Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PCOR120

3/55/16

<p>Licensee</p> <p>1. Allegan General Hospital</p> <p>2. 555 Linn Street Allegan, MI 49010</p>	<p>In accordance with letter dated June 16, 2006,</p> <p>3. License number 21-18659-01 is amended in its entirety as follows:</p> <p>4. Expiration date December 31, 2010</p> <p>5. Pocket No. 030-14003 Reference No.</p>
--	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Gadolinium-153</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed (not to exceed 1 curie of I-131)</p> <p>D. 4 sources, not to exceed 250 millicuries each</p>
---	--



9. Authorized Use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 excluding I-131 for thyroid carcinoma.

D. Two sources to be used in Adac Laboratories Transmission Line Source Housing VANTAGE devices for medical radiography in humans. Two sources in shipping containers for replacement of the sources.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-18659-01

Docket or Reference Number
030-14003

Amendment No. 22

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities located at 555 Linn Street, Allegan, Michigan.
- 11. The Radiation Safety Officer for this license is Philip J. Hartgerink, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for the materials and uses indicated:

Authorized Users

Material and Use

Michael S. Pawlik, D.O.

10 CFR 35.1001-35.200, (excluding generators, xenon-133 and aerosols) and gadolinium-153 in VANTAGE devices for medical radiography limited to cardiovascular clinical

Umakant S. Doctor, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures).

Stephen L. Peck, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures).

John A. Azevedo, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures).

Joel H. Reinoehl, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures).

Christopher Rogers, D.O.

10 CFR 35.200 (limited to cardiovascular clinical procedures).

Ramon Raneses, M.D.


10 CFR 35.200 (limited to cardiovascular clinical procedures).

Douglas J. Wunderly, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures).

John Schonder, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures).



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-18659-01

Docket or Reference Number
030-14003

Amendment No. 22

- James Lynch, M.D. 10 CFR 35.100, 35.200, and 35.300 (excluding iodine-131 for thyroid carcinoma).
- Philip J. Hartgerink, M.D. 10 CFR 35.100, 35.200, 35.300 (limited to sodium iodide-131 in quantities less than or equal to 33 millicuries), and gadolinium-153 in VANTAGE devices for medical radiography.
- Eric E. Ward, M.D. 10 CFR 35.100, 35.200 and gadolinium-153 in VANTAGE devices for medical radiography.
- Dennis A. Bruce, M.D. 10 CFR 35.100, 35.200 and gadolinium-153 in VANTAGE devices for medical radiography.
- Michael Jacoby, M.D. 10 CFR 35.100, 35.200 and gadolinium-153 in VANTAGE devices for medical radiography.

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license is limited only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in this license, and all correspondence are more restrictive than the regulations.
- A. Application dated June 30, 2000 (excluding any reference to the Quality Management Program); and
 - B. Letters dated August 31, 2000 (with attachments), March 12, 2001 (with attachments), June 6, 2001 (with enclosed close-out survey for Room C, former cardiac stress room in Radiology Department), August 7, 2001 and July 14, 2004 (with enclosures).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUL 21 2006

By *Toye L. Simmons*
 Toye L. Simmons
 Materials Licensing Branch
 Region III